Correspondence 0001213900-24-033266 from Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: April 16, 2024 · CIK: 0001601936 · Accession: 0001213900-24-033266
AI Filing Summary & Sentiment
File numbers found in text: 333-278594
Letter
Re: Altamira Therapeutics Ltd. (the “Company”)
April 16, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form F-1 (File No. 333-278594)
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on April 17, 2024, or as soon as practicable thereafter.
Please call Alex Dinur of Lowenstein Sandler LLP at 973-422-6732 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
ALTAMIRA THERAPEUTICS LTD.
Show Raw Text
CORRESP
1
filename1.htm
April 16, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Altamira Therapeutics Ltd. (the “Company”)
Registration Statement on Form F-1 (File No. 333-278594)
Ladies and Gentlemen:
In accordance with Rule 461
under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration
Statement”) be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on April 17, 2024, or as
soon as practicable thereafter.
Please call Alex Dinur of
Lowenstein Sandler LLP at 973-422-6732 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
ALTAMIRA THERAPEUTICS LTD.
By:
/s/ Thomas Meyer
Name:
Thomas Meyer
Title:
Chief Executive Officer